June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Extracellular Vesicles in Corneal Scarring
Author Affiliations & Notes
  • Gary Hin-Fai Yam
    Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
  • Footnotes
    Commercial Relationships   Gary Hin-Fai Yam None
  • Footnotes
    Support  Funds from Immune Transplant and Therapy Centre of UPMC; Hillman Foundation; Eye and Ear Foundation of Pittsburgh
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 2408. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Gary Hin-Fai Yam; Extracellular Vesicles in Corneal Scarring. Invest. Ophthalmol. Vis. Sci. 2023;64(8):2408.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Presentation Description : Corneal blindness due to scarring is treated with corneal tissue grafting. However, there exists a global challenge of donor material shortage. Various studies have shown that corneal stromal stem cells (CSSCs) suppress corneal scar formation. Mediated by the paracrine action of extracellular vesicles (EVs), CSSCs blocked neutrophil infiltration into the wound site and reduced fibrosis. Depletion of microRNAs in CSSC-derived EVs attenuated these regenerative effects. Our recent studies identified that these EVs delivered miR-29a and 381, which played important roles in anti-inflammation and fibrosis, and scar reduction after CSSC therapy. In addition, CSSC-EV cargo contained regenerative cytokine, transforming growth factor β3 (both protein and mRNA), which adds to the tissue regenerative effects of CSSC on corneal recovery after injury.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×